Today, August 30th, Chordate’s CEO Anders Weilandt presented the company’s Q2 report for 2024 on Finwire TV. He also answered questions from viewers and discussed, among other things, the expectations for Switzerland as a new focus market and the results of the company’s participation in investor conferences around the world.
“It’s clear that the market is very responsive; it reacts extremely well. I have the impression that it is a decentralized healthcare market where decisions can be made at much lower levels than, for example, in Sweden or England for that matter. And on top of that, we can add that Neurolite, our distributor, are very active in building and penetrating the market. They focus solely on neurology, so they are very knowledgeable and have well-established contacts and good trust from the healthcare side. I expect things to happen relatively frequently in Switzerland.”
“What has opened up through the conferences is a network of contacts that we were looking for in connection with the final steps in our exit process and our strategy in general. It’s important to ensure that the Chordate project and this rather fantastic treatment technology become well-known both among industrial stakeholders and partners, and among financial partners.”
Watch the full interview below (in Swedish):
